Indoco Remedies Ltd
NSE:INDOCO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Indoco Remedies Ltd
Note Receivable
Indoco Remedies Ltd
Note Receivable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Indoco Remedies Ltd
NSE:INDOCO
|
Note Receivable
₹989.7m
|
CAGR 3-Years
67%
|
CAGR 5-Years
35%
|
CAGR 10-Years
33%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Note Receivable
₹3.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Note Receivable
₹5.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
59%
|
CAGR 10-Years
7%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Note Receivable
₹2.6B
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-21%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Note Receivable
₹504.1m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-16%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Note Receivable
₹2.4B
|
CAGR 3-Years
28%
|
CAGR 5-Years
25%
|
CAGR 10-Years
2%
|
|
Indoco Remedies Ltd
Glance View
Indoco Remedies Ltd. engages in manufacturing and marketing of Formulations (Finished Dosage Forms) and active pharmaceutical ingredients. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2005-01-07. The firm is an integrated, research-oriented pharma company engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The firm's geographical segments include India and Outside India. The firm has nine domestic marketing divisions with a brand portfolio in various therapeutic segments, including Gastrointestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management and Gyneacology. The Company’s brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Cal-Aid, Cloben-G, Glychek, Kidodent, Carmicide, Rexidin, MCBM and Methycal.
See Also
What is Indoco Remedies Ltd's Note Receivable?
Note Receivable
989.7m
INR
Based on the financial report for Mar 31, 2025, Indoco Remedies Ltd's Note Receivable amounts to 989.7m INR.
What is Indoco Remedies Ltd's Note Receivable growth rate?
Note Receivable CAGR 10Y
33%
Over the last year, the Note Receivable growth was 1%. The average annual Note Receivable growth rates for Indoco Remedies Ltd have been 67% over the past three years , 35% over the past five years , and 33% over the past ten years .
